 |
|
Detection of glycoprotein could identify ovarian and uterine cancers with poor prognosis (p 865)
September 10, 2003Issue 13 September 2003
Embargoed 0001 h (London time) 12 September 2003.
The detection of a specific protein molecule could help oncologists identify uterine and ovarian cancers with poor prognosis and thereby enable better disease management of women with aggressive uterine or ovarian cancer, suggest authors of a study in this week's issue of THE LANCET.
Ovarian and uterine cancer is the most common cause of death from cancer-related deaths for women with gynaecological malignant disease. The prognosis for women with uterine cancer is usually better than for women with ovarian cancer; however some women will develop aggressive tumours in either disease which increases the risk of death.
Peter Altevogt from the German Cancer Research Centre, Heidelberg, Germany, and colleagues investigated whether a protein molecule (L1 glycoprotein) known to be involved in the spreading of malignant tumours was associated with the development of aggressive tumours for uterine and ovarian cancer.
The investigators used immunological and genetic assessments to identify L1 in uterine and ovarian cancers. L1 was found in 46 of 58 ovarian cancers and in 20 of 72 uterine cancers. L1 detection was a bad prognostic factor for patient survival. Patients with L1-positive uterine tumours were at high risk for progression even in the endometrioid-type tumours, which usually have a favourable prognosis.
Peter Altevogt comments: "Collectively, our results suggest that over-expression of L1 constitutes a new biomarker for ovarian and uterine carcinomas associated with poor clinical outcomeWell-designed prospective studies are needed to validate use of L1 expression in the classification and treatment of patients with ovarian and uterine carcinomas. L1-based diagnosis and prognosis could make an important contribution towards a better management and treatment of this disease."
Lancet
Ovarian Cancer News and Current Ovarian Cancer Events RSSVariation of normal protein could be key to resistance to common cancer drug
Researchers at the Moores Cancer Center at the University of California, San Diego (UC SD) in La Jolla have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.
New method to overcome multiple drug resistant diseases developed by Stanford researchers
Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them.
How chemo kills tumours: research to reduce side effects
Dr Stephen Taylor and Karen Gascoigne at the University's Faculty of Life Sciences have taken a new systematic approach to studying anti-mitotic drugs, which are used extensively for breast or ovarian cancer in the UK.
American Cancer Society study finds high use of complementary methods among cancer survivors
A new study from researchers at the American Cancer Society finds many cancer patients use complementary and alternative methods, most often prayer, relaxation, supplements, meditation, and massage.
Study finds that significant proportion of men told wife's cancer was incurable late or not at all
A study conducted in Sweden found that more than 40 percent of widowers in that country whose wives died from cancer four or five years earlier reported they were either never told that their spouse's cancer was incurable, or they heard this information during the last week of her life.
Symptom screening plus a simple blood test improves early detection of ovarian cancer
Women's reports of persistent, recent-onset symptoms linked to ovarian cancer - abdominal or pelvic pain, difficulty eating or feeling full quickly and abdominal bloating - when combined with the CA125 blood test may improve the early detection of ovarian cancer by 20 percent.
PET/CT scan could be valuable noninvasive tool for determining stages of ovarian cancer
Combined positron emission tomography (PET) and computed tomography (CT) scanning of patients in the early stages of ovarian cancer can enable physicians to determine whether the cancer has spread to nearby lymph nodes without having to perform surgery.
Glypican-3 gene function in regulating body size helps inform novel cancer treatments
In a leading study that has implications for the development of novel therapies for a number of breast, lung and ovarian cancers that have lost the expression of a gene called glypican-3 (GPC3), Sunnybrook researchers have discovered how the loss of the GPC3 gene induces overgrowth through certain growth factors such as Sonic Hedgehog which stimulate cancer growth.
Researchers identify new cell targets for preventing growth of breast and other tumors
Researchers at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have discovered new targets for cancer treatment aimed at blocking a key step in tumor progression.
Researchers identify new cell targets for preventing growth of breast and other tumors
Researchers at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have discovered new targets for cancer treatment aimed at blocking a key step in tumor progression.
More Ovarian Cancer News Articles
 | A Guide to Survivorship for Women with Ovarian Cancer (A Johns Hopkins Press Health Book) by F. J. Montz, Robert E. Bristow This comprehensive guide to ovarian cancer offers a wealth of information to ease the physical, emotional, and psychic suffering of women with the disease. The authors -- two Johns Hopkins gynecologic oncologists and a gynecologic-oncology clinical nurse -- put particular emphasis on the concept of "survivorship," or living life well in the face of daunting uncertainties. They stress the... |
 | It's My Ovaries, Stupid! by Elizabeth Lee Vliet This landmark work in women's health identifies and offers solutions to the hormonal dysfunctions afflicting millions of young women, teens, and even children, that rob women of future fertility and contribute to devastating problems -- from early onset puberty and obesity to depression and increased cancer risk. Women's health is more than breast cancer, pregnancy, and menopause. In this... |
 | Ovarian Cancer Journeys: Survivors Share Their Stories To Help Others by Ayala Miron "All of the research has reinforced that ovarian cancer is not a silent disease as was once thought and as is shown quite eloquently in this collection of stories.... The value of this collection of stories is that it helps raise awareness about symptoms, need for patient persistence, and the importance of being treated by a gynecologic oncologist." Barbara A. Goff, MD Professor and... |
 | 100 Questions & Answers About Ovarian Cancer, Second Edition by Don S. Dizon Whether you're a newly diagnosed ovarian cancer patient, a survivor, or a friend or relative of either, this completely updated second edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a gynecologic oncologist and a gynecologic surgeon, with actual patient commentary, ... |
 | No Time to Die:: Living with Ovarian Cancer by Liz Tilberis In 1993 Liz Tilberis seemed to have it all. She was a working mother with a family who adored her. As editor-in-chief of Harper's Bazzar, she lived at the center of the glamorous world of international fashion and was widely recognized as one of the most powerful people in the industry. And in 1993, Liz Tilberis was diagnosed with Stage III ovarian cancer.Suddenly she was faced with the challenge... |
 | Ovarian Cancer (Patient-Centered Guides) by Kristine Conner, Lauren Langford This unique guide for ovarian cancer gives women crucial medical information to improve the chance for lengthy remission and cure, as well as emotional support for the journey. Although many ovarian cancers are discovered after they have spread, having information about surgery and best practices can be life-saving. For example, choosing a surgeon from the new specialty of gynecologic oncology... |
 | Gilda's Disease: Sharing Personal Experiences and a Medical Perspective on Ovarian Cancer by Steven Piver The first book on ovarian cancer for the general reader, this is a comprehensive, compassionate look at a disease millions of people first became aware of with the tragic death of comedienne Gilda Radner in 1989. Dr. Piver, a leading cancer surgeon, discusses the causes of ovarian cancer, preventative measures, classic signs and symptoms, diagnostic tests and genetic screening, the different... |
 | A Feather in My Wig: Ovarian Cancer Cured, Seventeen Years and Going Strong! by Barbara R. Van Billiard With sensitivity and with humor, Barbara Van Billiard sets down the facts of her struggle and outlines the steps she took to deal with surgeries and chemotherapy. Her use of, and explanation, of various mind-body techniques, such as imagery and meditation, are a thought provoking approach that any cancer patient could use to help with life threatening... |
 | 100 Q&A About Ovarian Cancer by Don S. Dizon Covers a wide range of topics, including ovarian cancer; risk factors, diagnosis, treatment and side effects; and strategies for coping with emotional and healthcare... |
 | Surgery for Ovarian Cancer: Principles and Practice by Robert E. Bristow, Beth Y. Karlan A comprehensive surgical text, this book is designed to improve the reader's capability to implement important techniques essential to the effective management of ovarian cancer. With particular focus on the technical aspects of cytoreductive surgery, the book includes topics such as: pre-operative preparation, incisions/wound healing, surgical instrumentation, the management of apparent... |
| © 2008 BrightSurf.com |